| Trial ID: | L0531 |
| Source ID: | NCT03649711
|
| Associated Drug: |
Ticagrelor 90mg
|
| Title: |
Chronic Kidney Disease (CKD) Platelet Study
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT03649711/results
|
| Conditions: |
Chronic Kidney Diseases|Heart Attack|Stroke, Ischemic
|
| Interventions: |
DRUG: Ticagrelor 90mg|DRUG: Clopidogrel 75mg|DRUG: Aspirin 81 mg
|
| Outcome Measures: |
Primary: ADP Induced Platelet Aggregation, We will use summary statistics to describe the distribution of the data. Post-treatment ADP-induced WBPA value in ohms (Ω) will be the primary outcome variable. We will use an analysis of covariance (ANCOVA) model to compare the treatment effects of ticagrelor vs. clopidogrel in CKD patients because this approach has higher statistical power than other methods to analyze drug effects. T, 2 weeks | Secondary: Platelet Surface P-selectin Expression, Platelet surface P-selectin expression was measured using flow cytometry before and after treatment., 2 weeks
|
| Sponsor/Collaborators: |
Sponsor: University of Arkansas | Collaborators: American Society of Nephrology
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
76
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2018-11-01
|
| Completion Date: |
2021-09-02
|
| Results First Posted: |
2022-12-29
|
| Last Update Posted: |
2022-12-29
|
| Locations: |
Central Arkansas Veterans Affairs Hospital, Little Rock, Arkansas, 72205, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, 72205, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT03649711
|
